Dividends & Buybacks ·
Quantum Biopharma reports $11.3M in cash and digital assets with runway through January 2028
QNTMQuantum Biopharma Ltd.
Quantum Biopharma Ltd. filed a Form 6-K furnishing press releases from March 2025 to August 2026. Key events include the closing of debt settlements via share issuances, revisions to convertible debenture terms, and a private placement announcement. The filing also reports audited year-end financial results for December 31, 2025, noting $11.3 million in cash and digital assets, reduced operating expenses, and a 'No Going Concern' status with runway through January 2028. Additionally, it discloses the resignation of board member Terry Lynch and the completion of a special dividend distribution consisting of contingent value rights on October 27, 2025. Quantum Biopharma Ltd. is a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders.